[Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].

Authors :: Rexer H
Source :: Der Urologe. Ausg. A [Urologe A] 2011 Apr; Vol. 50 (4), pp. 489-92.
Publication Year :: 2011

Subjects :: Antineoplastic Agents therapeutic use
Chemotherapy, Adjuvant statistics & numerical data
Double-Blind Method
Germany epidemiology
Humans
Indazoles
Placebo Effect
Prevalence
Risk Assessment
Risk Factors
Survival Analysis
Survival Rate
Carcinoma, Renal Cell drug therapy
Carcinoma, Renal Cell mortality
Kidney Neoplasms mortality
Kidney Neoplasms therapy
Nephrectomy statistics & numerical data
Pyrimidines therapeutic use
Sulfonamides therapeutic use

Full Text Access

Tools